Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Thiotepa
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Shorla Gets FDA Nod for TEPYLUTE Vials to Treat Breast, Ovarian Cancer
Details : Tepylute, a ready-to-dilute formulation of thiotepa to treat breast and ovarian cancer, that eliminates the need for reconstitution.
Product Name : Tepylute
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 29, 2025
Lead Product(s) : Thiotepa
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Thiotepa
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Shorla Oncology Gets FDA Approval for TEPYLUTE for Breast and Ovarian Cancer
Details : FDA has approved the NDA for alkylating agent, TEPYLUTE (thiotepa), a ready-to-dilute infusion formulation to treat breast and ovarian cancer.
Product Name : Tepylute
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 28, 2024
Lead Product(s) : Thiotepa
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Thiotepa
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 24, 2020
Lead Product(s) : Thiotepa
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Thiotepa
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : ALL SCTped Forum | European Society for Blood and Marrow Transplantation | ALL-BFM Study Group | Assistance Publique – Hôpitaux de Paris | Dutch Childhood Oncology Group | Swiss Pediatric Oncology Group | Australian & New Zealand Children's Haematology/On
Deal Size : Inapplicable
Deal Type : Inapplicable
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 24, 2013
Lead Product(s) : Thiotepa
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : ALL SCTped Forum | European Society for Blood and Marrow Transplantation | ALL-BFM Study Group | Assistance Publique – Hôpitaux de Paris | Dutch Childhood Oncology Group | Swiss Pediatric Oncology Group | Australian & New Zealand Children's Haematology/On
Deal Size : Inapplicable
Deal Type : Inapplicable